Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06049134 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

StatusActive, Not Recruiting
PhasePhase 4
Started2023-10-06
View on ClinicalTrials.gov ↗

Amendment history

2026-03-05
Study Status v8
Primary completion date2026-03-01→2026-12-01
Completion date2027-08-01→2027-12-01
2026-02-12
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v7
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2025-08-07
Study Status v6
Primary completion date2025-08-01→2026-03-01
2025-05-12
Study Status v5
Re-verified, no change to tracked fields
2024-11-18
Study Status v4
Primary completion date2025-07-31→2025-08-01
Completion date2027-07-31→2027-08-01
Show 3 earlier versions
2024-05-13
Study Status v3
Completion date2025-07-31→2027-07-31
2023-10-06
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-03-31→confirmed 2023-10-06
Study sitesdetails revised at 1 of 1 site
2023-09-20
Study Identification, Study Status v1
Re-verified, no change to tracked fields
2023-09-15
Original filing
To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.
Trial Details
NCT Number NCT06049134
Lead Sponsor M.D. Anderson Cancer Center
Conditions Lymphoma
Enrollment 30 participants
Start Date 2023-10-06
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-15